The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor agonist , https://210list.com/story22405957/retatrutide-and-nmn-a-integrated-strategy-to-physiological-wellness